Aktienanalyse zu ProQR Therapeutics NV (PRQR)PRQRProQR Therapeutics NV

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ProQR Therapeutics is currently trading at $1.32, significantly below its 52-week high of $2.65, indicating potential upside. However, the stock has a low RSI of 39.15, suggesting it is nearing oversold territory, but it also reflects weak momentum. The company has a gross margin of 100%, which is excellent, but it has reported consistent net losses, with a net income loss of €13,383,000 in Q1 2026. The main risk is the company's ongoing financial losses and reliance on external financing, as evidenced by a recent direct offering that caused a 20% drop in share price. Given these factors, it may be prudent to hold rather than buy at this time, as the stock may need to stabilize before a clear buying opportunity arises.

4 analysts cover PRQR: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.67.